Europe Oncology Anti-Cancer Drugs Market Report 2019

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

In this report, the Oncology Anti-Cancer Drugs market is expected to be valued at USD xxx billion by 2026, growing at a CAGR of xx% between 2020 and 2026. In this study, sales and sales value (million USD) of major players in Europe market will be included. Sales and revenue by type/application from 2014-2026. Industry chain, market trend, downstream and upstream information is also included. Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Oncology Anti-Cancer Drugs for these regions, from 2014 to 2026 (forecast), including Germany UK France Russia Benelux Italy Spain Europe Oncology Anti-Cancer Drugs market competition by top manufacturers/players, with Oncology Anti-Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including Amgen AstraZeneca Roche Diagnostics GlaxoSmithKline Merck Novartis AbbVie Sanofi EIMC United Pharmaceuticals Actavis On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into Chemotherapy Targeted Therapy Immunotherapy (Biologic Therapy) Hormonal Therapy Others On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Oncology Anti-Cancer Drugs for each application, including Blood Cancer (Leukaemia) Breast Cancer Gastrointestinal Cancer Respiratory/Lung Cancer Skin Cancer Other Cancers If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

1 Report Overview
    1.1 Definition and Specification
    1.2 Report Overview
        1.2.1 Manufacturers Overview
        1.2.2 Regions Overview
        1.2.3 Type Overview
        1.2.4 Application Overview
    1.3 Industrial Chain
        1.3.1 Oncology Anti-Cancer Drugs Overall Industrial Chain
        1.3.2 Upstream
        1.3.3 Downstream
    1.4 Industry Situation
        1.4.1 Industrial Policy
        1.4.2 Product Preference
        1.4.3 Economic/Political Environment
    1.5 SWOT Analysis
2 Market Analysis by Types
    2.1 Overall Market Performance(Volume)
             2.1.1 Chemotherapy Market Performance (Volume)
             2.1.2 Targeted Therapy Market Performance (Volume)
             2.1.3 Immunotherapy (Biologic Therapy) Market Performance (Volume)
             2.1.4 Hormonal Therapy Market Performance (Volume)
             2.1.5 Others Market Performance (Volume)
    2.2 Overall Market Performance(Value)
             2.2.1 Chemotherapy Market Performance (Value)
             2.2.2 Targeted Therapy Market Performance (Value)
             2.2.3 Immunotherapy (Biologic Therapy) Market Performance (Value)
             2.2.4 Hormonal Therapy Market Performance (Value)
             2.2.5 Others Market Performance (Value)
3 Product Application Market
    3.1 Overall Market Performance (Volume)
             3.1.1 Blood Cancer (Leukaemia) Market Performance (Volume)
             3.1.2 Breast Cancer Market Performance (Volume)
             3.1.3 Gastrointestinal Cancer Market Performance (Volume)
             3.1.4 Respiratory/Lung Cancer Market Performance (Volume)
             3.1.5 Skin Cancer Market Performance (Volume)
             3.1.6 Other Cancers Market Performance (Volume)
4 Manufacturers Profiles/Analysis
    4.1 Amgen
        4.1.1 Amgen Profiles
        4.1.2 Amgen Product Information
        4.1.3 Amgen Oncology Anti-Cancer Drugs Business Performance
        4.1.4 Amgen Oncology Anti-Cancer Drugs Business Development and Market Status
    4.2 AstraZeneca
        4.2.1 AstraZeneca Profiles
        4.2.2 AstraZeneca Product Information
        4.2.3 AstraZeneca Oncology Anti-Cancer Drugs Business Performance
        4.2.4 AstraZeneca Oncology Anti-Cancer Drugs Business Development and Market Status
    4.3 Roche Diagnostics
        4.3.1 Roche Diagnostics Profiles
        4.3.2 Roche Diagnostics Product Information
        4.3.3 Roche Diagnostics Oncology Anti-Cancer Drugs Business Performance
        4.3.4 Roche Diagnostics Oncology Anti-Cancer Drugs Business Development and Market Status
    4.4 GlaxoSmithKline
        4.4.1 GlaxoSmithKline Profiles
        4.4.2 GlaxoSmithKline Product Information
        4.4.3 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Performance
        4.4.4 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Development and Market Status
    4.5 Merck
        4.5.1 Merck Profiles
        4.5.2 Merck Product Information
        4.5.3 Merck Oncology Anti-Cancer Drugs Business Performance
        4.5.4 Merck Oncology Anti-Cancer Drugs Business Development and Market Status
    4.6 Novartis
        4.6.1 Novartis Profiles
        4.6.2 Novartis Product Information
        4.6.3 Novartis Oncology Anti-Cancer Drugs Business Performance
        4.6.4 Novartis Oncology Anti-Cancer Drugs Business Development and Market Status
    4.7 AbbVie
        4.7.1 AbbVie Profiles
        4.7.2 AbbVie Product Information
        4.7.3 AbbVie Oncology Anti-Cancer Drugs Business Performance
        4.7.4 AbbVie Oncology Anti-Cancer Drugs Business Development and Market Status
    4.8 Sanofi
        4.8.1 Sanofi Profiles
        4.8.2 Sanofi Product Information
        4.8.3 Sanofi Oncology Anti-Cancer Drugs Business Performance
        4.8.4 Sanofi Oncology Anti-Cancer Drugs Business Development and Market Status
    4.9 EIMC United Pharmaceuticals
        4.9.1 EIMC United Pharmaceuticals Profiles
        4.9.2 EIMC United Pharmaceuticals Product Information
        4.9.3 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Performance
        4.9.4 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Development and Market Status
    4.10 Actavis
        4.10.1 Actavis Profiles
        4.10.2 Actavis Product Information
        4.10.3 Actavis Oncology Anti-Cancer Drugs Business Performance
        4.10.4 Actavis Oncology Anti-Cancer Drugs Business Development and Market Status
5 Market Performance for Manufacturers
    5.1 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
    5.2 Europe Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
    5.3 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
    5.4 Europe Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
    5.5 Market Concentration
6 Regions Market Performance for Manufacturers
    6.1 Germany Market Performance for Manufacturers
        6.1.1 Germany Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.1.2 Germany Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.1.3 Germany Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.1.4 Germany Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.1.5 Market Concentration
    6.2 UK Market Performance for Manufacturers
        6.2.1 UK Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.2.2 UK Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.2.3 UK Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.2.4 UK Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.2.5 Market Concentration
    6.3 France Market Performance for Manufacturers
        6.3.1 France Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.3.2 France Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.3.3 France Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.3.4 France Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.3.5 Market Concentration
    6.4 Russia Market Performance for Manufacturers
        6.4.1 Russia Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.4.2 Russia Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.4.3 Russia Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.4.4 Russia Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.4.5 Market Concentration
    6.5 Benelux Market Performance for Manufacturers
        6.5.1 Benelux Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.5.2 Benelux Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.5.3 Benelux Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.5.4 Benelux Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.5.5 Market Concentration
    6.6 Italy Market Performance for Manufacturers
        6.6.1 Italy Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.6.2 Italy Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.6.3 Italy Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.6.4 Italy Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.6.5 Market Concentration
    6.7 Spain Market Performance for Manufacturers
        6.7.1 Spain Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.7.2 Spain Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.7.3 Spain Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.7.4 Spain Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.7.5 Market Concentration
    6.8  Market Performance for Manufacturers
        6.8.1  Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.8.2  Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.8.3  Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.8.4  Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.8.5 Market Concentration
7 Europe  Oncology Anti-Cancer Drugs Market Performance (Sales Point)
    7.1 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Regions 2014-2020
    7.2 Europe Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Regions 2014-2020
    7.3 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) by Regions 2014-2020
    7.4 Europe Oncology Anti-Cancer Drugs Gross Margin by Regions 2014-2020
8 Development Trend for Regions (Sales Point)
    8.1 Europe Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.2 Germany Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.3 UK Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.4 France Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.5 Russia Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.6 Benelux Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.7 Italy Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.8 Spain Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
9 Upstream Source, Technology and Cost
    9.1 Upstream Source
    9.2 Technology
    9.3 Cost
10 Channel Analysis
    10.1 Market Channel
    10.2 Distributors
11 Consumer Analysis
    11.1 Blood Cancer (Leukaemia) Industry
    11.2 Breast Cancer Industry
    11.3 Gastrointestinal Cancer Industry
    11.4 Respiratory/Lung Cancer Industry
    11.5 Skin Cancer Industry
    11.6 Other Cancers Industry
12 Market Forecast 2021-2026
    12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
        12.1.1 Europe Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
        12.1.2 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Growth Rate 2021-2026
        12.1.3 Germany Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.4 UK Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.5 France Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.6 Russia Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.7 Benelux Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.8 Italy Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.9 Spain Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
        12.2.1 Overall Market Performance
        12.2.2 Chemotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.2.3 Targeted Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.2.4 Immunotherapy (Biologic Therapy) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.2.5 Hormonal Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.2.6 Others Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    12.3 Sales Forecast by Application 2021-2026
        12.3.1 Overall Market Performance
        12.3.2 Blood Cancer (Leukaemia) Sales and and Growth Rate 2021-2026
        12.3.3 Breast Cancer Sales and and Growth Rate 2021-2026
        12.3.4 Gastrointestinal Cancer Sales and and Growth Rate 2021-2026
        12.3.5 Respiratory/Lung Cancer Sales and and Growth Rate 2021-2026
        12.3.6 Skin Cancer Sales and and Growth Rate 2021-2026
        12.3.7 Other Cancers Sales and and Growth Rate 2021-2026
    12.4 Price (USD/Unit) and Gross Profit Forecast
        12.4.1 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) Trend 2021-2026
        12.4.2 Europe Oncology Anti-Cancer Drugs Gross Profit Trend 2021-2026
13 Conclusion
Chemicals and Materials

Global Fertilizer Anti-Caking Agents Market Status and Future Forecast 2015-2025

  Price : US$ 4,500   Date : Mar 2020
  Category : Chemicals and Materials   Pages : 131
Chemicals and Materials

Global Marine Anti-Fouling Coatings Market Status and Future Forecast 2015-2025

  Price : US$ 4,500   Date : Mar 2020
  Category : Chemicals and Materials   Pages : 134
Chemicals and Materials

Global Anti Slip Coatings Market Status and Future Forecast 2015-2025

  Price : US$ 4,500   Date : Mar 2020
  Category : Chemicals and Materials   Pages : 139
Chemicals and Materials

Global Anti-bacteria Coating Market Status and Future Forecast 2015-2025

  Price : US$ 4,500   Date : Mar 2020
  Category : Chemicals and Materials   Pages : 133
Medical Devices

Global Thin Film Drugs Market Status and Future Forecast 2015-2025

  Price : US$ 4,500   Date : Mar 2020
  Category : Medical Devices   Pages : 161

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports 203, 2nd Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).

Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2020 Worldwide Market Reports. All rights reserved